Loeys-Dietz syndrome (LDS) is an autosomal dominant connective tissue disorder caused by heterozygous mutations in genes encoding components of the TGF-beta signaling pathway, most commonly TGFBR1 and TGFBR2. It is characterized by the triad of arterial tortuosity and aneurysms, hypertelorism, and bifid uvula or cleft palate. Additional features include craniosynostosis, skeletal abnormalities (scoliosis, pectus deformity, joint laxity or contractures), thin translucent skin, and immunologic features (food allergy, eosinophilic gastrointestinal disease). LDS carries a high risk of aortic dissection at smaller aortic diameters than Marfan syndrome, with a mean age at death of 26.0 years in initial cohorts. Early diagnosis and aggressive surgical management are critical.
Ask a research question about Loeys-Dietz Syndrome. OpenScientist will conduct autonomous deep research using the Disorder Mechanisms Knowledge Base and PubMed literature (typically 10-30 minutes).
Do not include personal health information in your question. Questions and results are cached in your browser's local storage.
name: Loeys-Dietz Syndrome
creation_date: '2026-02-13T00:31:42Z'
updated_date: '2026-04-28T18:00:00Z'
category: Mendelian
description: >
Loeys-Dietz syndrome (LDS) is an autosomal dominant connective tissue disorder
caused by heterozygous mutations in genes encoding components of the TGF-beta
signaling pathway, most commonly TGFBR1 and TGFBR2. It is characterized by the
triad of arterial tortuosity and aneurysms, hypertelorism, and bifid uvula or
cleft palate. Additional features include craniosynostosis, skeletal abnormalities
(scoliosis, pectus deformity, joint laxity or contractures), thin translucent skin,
and immunologic features (food allergy, eosinophilic gastrointestinal disease).
LDS carries a high risk of aortic dissection at smaller aortic diameters than
Marfan syndrome, with a mean age at death of 26.0 years in initial cohorts.
Early diagnosis and aggressive surgical management are critical.
disease_term:
preferred_term: Loeys-Dietz syndrome
term:
id: MONDO:0018954
label: Loeys-Dietz syndrome
definitions:
- name: Orphanet disease definition
definition_type: CASE_DEFINITION
description: >
Orphanet defines Loeys-Dietz syndrome as a rare genetic connective tissue
disorder characterized by a broad spectrum of craniofacial, vascular and
skeletal manifestations with four genetic subtypes described forming a
clinical continuum.
evidence:
- reference: ORPHA:60030
reference_title: "Loeys-Dietz syndrome (Orphanet structured-database record)"
supports: SUPPORT
evidence_source: OTHER
snippet: "Loeys-Dietz syndrome is a rare genetic connective tissue disorder characterized by a broad spectrum of craniofacial, vascular and skeletal manifestations with four genetic subtypes described forming a clinical continuum."
explanation: Orphanet's definition supports the multisystem connective-tissue framing of this entry.
external_assertions:
- name: Orphanet Loeys-Dietz syndrome record
source: Orphanet
assertion_type: Structured disease record
external_id: ORPHA:60030
url: http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=60030
description: >
Orphanet structured record for Loeys-Dietz syndrome, including curated
cross-references to MONDO, ICD-10, ICD-11, OMIM, MeSH, MedDRA, and UMLS
identifiers.
evidence:
- reference: ORPHA:60030
reference_title: "Loeys-Dietz syndrome (Orphanet structured-database record)"
supports: SUPPORT
evidence_source: OTHER
snippet: "MONDO:0018954 | Exact"
explanation: The Orphanet cross-reference table exactly maps ORPHA:60030 to MONDO:0018954.
- reference: ORPHA:60030
reference_title: "Loeys-Dietz syndrome (Orphanet structured-database record)"
supports: SUPPORT
evidence_source: OTHER
snippet: "ICD-10:Q87.4 | Narrower"
explanation: The Orphanet cross-reference table maps ORPHA:60030 to ICD-10 Q87.4 with a Narrower mapping.
- reference: ORPHA:60030
reference_title: "Loeys-Dietz syndrome (Orphanet structured-database record)"
supports: SUPPORT
evidence_source: OTHER
snippet: "UMLS:C2697932 | Exact"
explanation: The Orphanet cross-reference table exactly maps ORPHA:60030 to UMLS C2697932.
parents:
- Connective Tissue Disorders
- Marfan and Marfan-related Disorders
has_subtypes:
- name: Loeys-Dietz Syndrome Type 1
description: >
Caused by mutations in TGFBR1. Often presents with more severe
craniofacial features including craniosynostosis. Earlier cardiovascular
surgery (mean age 16.9 years) and death (22.6 years) compared to type 2.
- name: Loeys-Dietz Syndrome Type 2
description: >
Caused by mutations in TGFBR2. More prominent cutaneous features
and phenotypic overlap with vascular Ehlers-Danlos syndrome.
Later surgery (mean age 26.9 years) and death (31.8 years) than type 1.
- name: Loeys-Dietz Syndrome Type 3
description: >
Caused by mutations in SMAD3. Associated with early-onset osteoarthritis
(aneurysms-osteoarthritis syndrome) and increased prevalence of mitral
valve prolapse.
- name: Loeys-Dietz Syndrome Type 4
description: >
Caused by mutations in TGFB2. Generally milder vascular phenotype
with lower prevalence of musculoskeletal involvement.
- name: Loeys-Dietz Syndrome Type 5
description: >
Caused by mutations in TGFB3. Milder phenotype with variable penetrance.
inheritance:
- name: Autosomal Dominant
description: >
Autosomal dominant inheritance with variable expressivity.
evidence:
- reference: PMID:24577266
reference_title: "Loeys-Dietz syndrome: a primer for diagnosis and management."
supports: SUPPORT
snippet: >-
LDS, an autosomal-dominant connective tissue disorder first
characterized by aortic aneurysms and generalized arterial tortuosity,
hypertelorism, and bifid/broad uvula or cleft palate
explanation: >-
MacCarrick et al. confirm autosomal dominant inheritance in this
comprehensive clinical management review.
- reference: ORPHA:60030
reference_title: "Loeys-Dietz syndrome (Orphanet structured-database record)"
supports: SUPPORT
evidence_source: OTHER
snippet: "Autosomal dominant"
explanation: Orphanet records autosomal dominant inheritance for Loeys-Dietz syndrome.
- name: Autosomal Recessive
description: >
Rare autosomal recessive inheritance has been reported for Loeys-Dietz
syndrome, per Orphanet curation.
evidence:
- reference: ORPHA:60030
reference_title: "Loeys-Dietz syndrome (Orphanet structured-database record)"
supports: SUPPORT
evidence_source: OTHER
snippet: "Autosomal recessive"
explanation: Orphanet records autosomal recessive as an additional inheritance pattern for Loeys-Dietz syndrome.
prevalence:
- population: General population
percentage: less than 1 in 100,000
notes: >-
The prevalence estimate located in PubMed is based on clinical literature
rather than population-wide ascertainment, but it gives a usable upper-bound
estimate for this rare connective tissue disorder.
evidence:
- reference: PMID:32339686
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
The prevalence of LDS is estimated to be less than 1 in 100,000.
explanation: >-
This abstract provides an explicit prevalence estimate for Loeys-Dietz
syndrome.
- population: Worldwide (Orphanet)
notes: >-
Orphanet epidemiology record references the landmark Loeys et al. 2006
cohort with unknown point prevalence worldwide.
evidence:
- reference: ORPHA:60030
reference_title: "Loeys-Dietz syndrome (Orphanet structured-database record)"
supports: SUPPORT
evidence_source: OTHER
snippet: "Unknown | Worldwide | Point prevalence | ORPHANET_16928994[PMID"
explanation: Orphanet records worldwide point prevalence as unknown, referencing the landmark PMID:16928994 study.
progression:
- phase: Onset
age_range: Antenatal to Infancy
evidence:
- reference: ORPHA:60030
reference_title: "Loeys-Dietz syndrome (Orphanet structured-database record)"
supports: SUPPORT
evidence_source: OTHER
snippet: "Age of onset: Antenatal"
explanation: Orphanet records antenatal as an age-of-onset category for Loeys-Dietz syndrome.
pathophysiology:
- name: Paradoxical TGF-beta Signaling
conforms_to: "aortopathy_tgfbeta_dysregulation#TGF-beta Signaling Dysregulation"
description: >
Loss-of-function mutations in TGF-beta receptors paradoxically lead to
increased TGF-beta signaling in the aortic wall, mediated through
non-canonical pathways and compensatory upregulation. This results in
excessive SMAD2/3 phosphorylation and activation of ERK and p38 MAPK
downstream targets that promote extracellular matrix degradation.
cell_types:
- preferred_term: Vascular Smooth Muscle Cell
term:
id: CL:0000359
label: vascular associated smooth muscle cell
- preferred_term: Fibroblast
term:
id: CL:0000057
label: fibroblast
biological_processes:
- preferred_term: TGF-beta Signaling
term:
id: GO:0007179
label: transforming growth factor beta receptor signaling pathway
modifier: INCREASED
- preferred_term: SMAD Signaling
term:
id: GO:0060395
label: SMAD protein signal transduction
modifier: INCREASED
downstream:
- target: Extracellular Matrix Degradation
description: >-
Enhanced TGF-beta/SMAD signaling drives matrix metalloproteinase
upregulation and degradation of the aortic wall extracellular matrix.
evidence:
- reference: PMID:21493862
reference_title: "Noncanonical TGFβ signaling contributes to aortic aneurysm progression in Marfan syndrome mice."
supports: SUPPORT
evidence_source: MODEL_ORGANISM
snippet: >-
extracellular signal-regulated kinase (ERK) 1 and 2 and Smad2
are activated in a mouse model of MFS, and both are inhibited by
therapies directed against TGFbeta
explanation: >-
Holm et al. demonstrate that both canonical (Smad2) and noncanonical
(ERK1/2) TGF-beta signaling are activated in aortic disease, and
selective ERK1/2 inhibition ameliorates aortic growth while Smad4
deficiency exacerbates disease.
- reference: PMID:16928994
reference_title: "Aneurysm syndromes caused by mutations in the TGF-beta receptor."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
The disease is characterized by the triad of arterial tortuosity and
aneurysms, hypertelorism, and bifid uvula or cleft palate and is
caused by heterozygous mutations in the genes encoding transforming
growth factor beta receptors 1 and 2 (TGFBR1 and TGFBR2, respectively)
explanation: >-
The landmark Loeys et al. 2006 NEJM paper establishes TGF-beta receptor
mutations as the cause and defines the clinical triad.
- name: Noncanonical MAPK Pathway Activation
description: >
In addition to canonical SMAD signaling, noncanonical ERK1/2 and JNK
pathways are prominently activated in LDS aortic tissue. Selective
inhibition of ERK1/2 ameliorates aortic growth, while JNK antagonism
is also protective. These non-SMAD pathways may be the primary
drivers of aortic disease progression.
biological_processes:
- preferred_term: ERK Cascade
term:
id: GO:0070371
label: ERK1 and ERK2 cascade
- preferred_term: JNK Cascade
term:
id: GO:0007254
label: JNK cascade
evidence:
- reference: PMID:21493862
reference_title: "Noncanonical TGFβ signaling contributes to aortic aneurysm progression in Marfan syndrome mice."
supports: SUPPORT
evidence_source: MODEL_ORGANISM
snippet: >-
noncanonical (Smad-independent) TGFbeta signaling is a prominent driver
of aortic disease in MFS mice, and inhibition of the ERK1/2 or JNK1
pathways is a potential therapeutic strategy for the disease
explanation: >-
Holm et al. establish noncanonical TGF-beta signaling via ERK and JNK
as key drivers of aortic aneurysm progression.
- name: Extracellular Matrix Degradation
conforms_to: "aortopathy_tgfbeta_dysregulation#Aortic Medial Degeneration and Wall Weakening"
description: >
Enhanced TGF-beta signaling leads to upregulation of matrix
metalloproteinases (MMPs) and reduced expression of tissue inhibitors,
causing degradation of elastic fibers and collagen in the arterial wall.
This weakens the vessel wall leading to aneurysm formation and dissection.
cell_types:
- preferred_term: vascular associated smooth muscle cell
term:
id: CL:0000359
label: vascular associated smooth muscle cell
biological_processes:
- preferred_term: Extracellular Matrix Disassembly
term:
id: GO:0022617
label: extracellular matrix disassembly
modifier: INCREASED
- preferred_term: Elastic Fiber Assembly
term:
id: GO:0048251
label: elastic fiber assembly
modifier: DECREASED
locations:
- preferred_term: Aorta
term:
id: UBERON:0000947
label: aorta
downstream:
- target: Aortic Aneurysm
description: >-
Degradation of elastic fibers and collagen weakens the aortic media,
promoting aneurysmal dilation.
- target: Aortic Dissection
description: >-
Progressive medial weakening predisposes to dissection, characteristically
at smaller aortic diameters than in Marfan syndrome.
- name: Skeletal Development Disruption
description: >
TGF-beta signaling is critical for skeletal development, particularly
in suture closure and vertebral column formation. Dysregulated signaling
leads to craniosynostosis, scoliosis, and cervical spine instability.
Cervical spine findings are prominent in LDS 1/2 (51% of patients).
biological_processes:
- preferred_term: Skeletal System Development
term:
id: GO:0001501
label: skeletal system development
- preferred_term: Cranial Suture Morphogenesis
term:
id: GO:0060363
label: cranial suture morphogenesis
evidence:
- reference: PMID:24577266
reference_title: "Loeys-Dietz syndrome: a primer for diagnosis and management."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Cervical spine findings are prominent features in LDS 1/2 (51%),
but presence in LDS 3 and 4 is unknown
explanation: >-
MacCarrick et al. document cervical spine abnormalities in over
half of LDS type 1/2 patients.
- name: Immune Dysregulation
description: >
LDS is associated with a high prevalence of immunologic features
including food allergy (31%), eosinophilic gastrointestinal disease,
asthma, eczema, and allergic rhinitis. TGF-beta pathway disruption
affects immune regulation and mucosal tolerance.
biological_processes:
- preferred_term: Immune Response Regulation
term:
id: GO:0050776
label: regulation of immune response
evidence:
- reference: PMID:24577266
reference_title: "Loeys-Dietz syndrome: a primer for diagnosis and management."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
LDS has been associated with a high prevalence of immunologic features
including asthma, food allergy, eczema, and allergic rhinitis
explanation: >-
MacCarrick et al. document significant immune dysregulation in LDS,
with food allergy prevalence of 31% compared to 6-8% in the
general population.
phenotypes:
- name: Aortic Aneurysm
description: >
Progressive aortic aneurysm, a hallmark vascular feature. Orphanet classifies
aortic aneurysm as Very frequent (99-80%) in LDS.
frequency: VERY_FREQUENT
phenotype_term:
preferred_term: Aortic aneurysm
term:
id: HP:0004942
label: Aortic aneurysm
evidence:
- reference: PMID:16928994
reference_title: "Aneurysm syndromes caused by mutations in the TGF-beta receptor."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
The natural history of both types was characterized by aggressive
arterial aneurysms (mean age at death, 26.0 years) and a high
incidence of pregnancy-related complications (in 6 of 12 women)
explanation: >-
Loeys et al. document aggressive aneurysmal disease with early mortality
in 52 families with LDS.
- reference: ORPHA:60030
reference_title: "Loeys-Dietz syndrome (Orphanet structured-database record)"
supports: SUPPORT
evidence_source: OTHER
snippet: "HP:0004942 | Aortic aneurysm | Very frequent (99-80%)"
explanation: Orphanet's curated HPO frequency annotation classifies aortic aneurysm as Very frequent (99-80%) in Loeys-Dietz syndrome.
- name: Aortic Root Aneurysm
description: >
Progressive dilation of the aortic root, occurring at earlier ages and
smaller diameters than in Marfan syndrome. Dissections have occurred
at aortic dimensions of 3.9-4.0 cm, unlike the 5.0 cm threshold
in Marfan syndrome.
phenotype_term:
preferred_term: Aortic root aneurysm
term:
id: HP:0002616
label: Aortic root aneurysm
evidence:
- reference: PMID:24577266
reference_title: "Loeys-Dietz syndrome: a primer for diagnosis and management."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
dissections have occurred in individuals with LDS 1, 2, or 3 at
aortic dimensions of 3.9-4.0 cm
explanation: >-
MacCarrick et al. note dissections at smaller diameters than Marfan
syndrome, supporting more aggressive surgical thresholds.
- name: Aortic Dissection
description: >
Aortic dissection is a life-threatening complication occurring at smaller
aortic diameters than in Marfan syndrome. Orphanet classifies this as
Very frequent (99-80%).
frequency: VERY_FREQUENT
phenotype_term:
preferred_term: Aortic dissection
term:
id: HP:0002647
label: Aortic dissection
evidence:
- reference: PMID:16928994
reference_title: "Aneurysm syndromes caused by mutations in the TGF-beta receptor."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
The natural history of both types was characterized by aggressive
arterial aneurysms (mean age at death, 26.0 years) and a high
incidence of pregnancy-related complications (in 6 of 12 women)
explanation: >-
Loeys et al. document aggressive aneurysmal disease leading to
dissection and early mortality.
- reference: ORPHA:60030
reference_title: "Loeys-Dietz syndrome (Orphanet structured-database record)"
supports: SUPPORT
evidence_source: OTHER
snippet: "HP:0002647 | Aortic dissection | Very frequent (99-80%)"
explanation: Orphanet's curated HPO frequency annotation classifies aortic dissection as Very frequent (99-80%) in Loeys-Dietz syndrome.
- name: Arterial Tortuosity
description: >
Widespread arterial tortuosity, particularly of the head and neck
vessels. A distinguishing feature from Marfan syndrome. Increased
vertebral arterial tortuosity is a marker of adverse aortic outcome.
frequency: VERY_FREQUENT
phenotype_term:
preferred_term: Arterial tortuosity
term:
id: HP:0005116
label: Arterial tortuosity
evidence:
- reference: PMID:35662564
reference_title: "Clinical features and complications of Loeys-Dietz syndrome: A systematic review."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
the most commonly reported features and complications being: aortic
aneurysms and dissections, arterial tortuosity, high arched palate,
abnormal uvula and hypertelorism
explanation: >-
Systematic review of 3896 LDS cases confirms arterial tortuosity
as one of the most common features.
- reference: ORPHA:60030
reference_title: "Loeys-Dietz syndrome (Orphanet structured-database record)"
supports: SUPPORT
evidence_source: OTHER
snippet: "HP:0005116 | Arterial tortuosity | Very frequent (99-80%)"
explanation: Orphanet's curated HPO frequency annotation classifies arterial tortuosity as Very frequent (99-80%) in Loeys-Dietz syndrome.
- name: Arterial Dissection
description: >
Dissection can occur in arteries throughout the body, not just the aorta.
Orphanet classifies arterial dissection as Very frequent (99-80%).
frequency: VERY_FREQUENT
phenotype_term:
preferred_term: Arterial dissection
term:
id: HP:0005294
label: Arterial dissection
evidence:
- reference: ORPHA:60030
reference_title: "Loeys-Dietz syndrome (Orphanet structured-database record)"
supports: SUPPORT
evidence_source: OTHER
snippet: "HP:0005294 | Arterial dissection | Very frequent (99-80%)"
explanation: Orphanet's curated HPO frequency annotation classifies arterial dissection as Very frequent (99-80%) in Loeys-Dietz syndrome.
- name: Hypertelorism
description: >
Wide-spaced eyes, part of the characteristic craniofacial gestalt
and the diagnostic triad.
frequency: FREQUENT
phenotype_term:
preferred_term: Hypertelorism
term:
id: HP:0000316
label: Hypertelorism
evidence:
- reference: PMID:16928994
reference_title: "Aneurysm syndromes caused by mutations in the TGF-beta receptor."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
The disease is characterized by the triad of arterial tortuosity and
aneurysms, hypertelorism, and bifid uvula or cleft palate
explanation: >-
Hypertelorism is part of the defining diagnostic triad.
- reference: ORPHA:60030
reference_title: "Loeys-Dietz syndrome (Orphanet structured-database record)"
supports: SUPPORT
evidence_source: OTHER
snippet: "HP:0000316 | Hypertelorism | Frequent (79-30%)"
explanation: Orphanet's curated HPO frequency annotation classifies hypertelorism as Frequent (79-30%) in Loeys-Dietz syndrome.
- name: Bifid Uvula
description: >
Bifid or broad uvula, a hallmark feature often used for clinical
screening. May range from broad uvula to overt cleft palate.
frequency: FREQUENT
phenotype_term:
preferred_term: Bifid uvula
term:
id: HP:0000193
label: Bifid uvula
evidence:
- reference: PMID:16928994
reference_title: "Aneurysm syndromes caused by mutations in the TGF-beta receptor."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
The disease is characterized by the triad of arterial tortuosity and
aneurysms, hypertelorism, and bifid uvula or cleft palate
explanation: >-
Bifid uvula is part of the defining diagnostic triad.
- reference: ORPHA:60030
reference_title: "Loeys-Dietz syndrome (Orphanet structured-database record)"
supports: SUPPORT
evidence_source: OTHER
snippet: "HP:0000193 | Bifid uvula | Frequent (79-30%)"
explanation: Orphanet's curated HPO frequency annotation classifies bifid uvula as Frequent (79-30%) in Loeys-Dietz syndrome.
- name: Cleft Palate
description: >
Cleft palate, ranging from submucous to overt, is part of the
craniofacial spectrum of LDS.
frequency: FREQUENT
phenotype_term:
preferred_term: Cleft palate
term:
id: HP:0000175
label: Cleft palate
evidence:
- reference: ORPHA:60030
reference_title: "Loeys-Dietz syndrome (Orphanet structured-database record)"
supports: SUPPORT
evidence_source: OTHER
snippet: "HP:0000175 | Cleft palate | Frequent (79-30%)"
explanation: Orphanet's curated HPO frequency annotation classifies cleft palate as Frequent (79-30%) in Loeys-Dietz syndrome.
- name: Craniosynostosis
description: >
Premature fusion of cranial sutures, most commonly the sagittal suture
but also coronal, metopic, and squamosal. More common in LDS type 1.
frequency: FREQUENT
phenotype_term:
preferred_term: Craniosynostosis
term:
id: HP:0001363
label: Craniosynostosis
evidence:
- reference: PMID:24577266
reference_title: "Loeys-Dietz syndrome: a primer for diagnosis and management."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Most commonly, the sagittal suture is prematurely closed, but the
coronal, metopic, and squamosal sutures can also be involved
explanation: >-
MacCarrick et al. describe the pattern of suture involvement in LDS
craniosynostosis.
- reference: ORPHA:60030
reference_title: "Loeys-Dietz syndrome (Orphanet structured-database record)"
supports: SUPPORT
evidence_source: OTHER
snippet: "HP:0001363 | Craniosynostosis | Frequent (79-30%)"
explanation: Orphanet's curated HPO frequency annotation classifies craniosynostosis as Frequent (79-30%) in Loeys-Dietz syndrome.
- name: Scoliosis
description: >
Progressive scoliosis requiring monitoring and potential surgical
intervention.
frequency: FREQUENT
phenotype_term:
preferred_term: Scoliosis
term:
id: HP:0002650
label: Scoliosis
evidence:
- reference: ORPHA:60030
reference_title: "Loeys-Dietz syndrome (Orphanet structured-database record)"
supports: SUPPORT
evidence_source: OTHER
snippet: "HP:0002650 | Scoliosis | Frequent (79-30%)"
explanation: Orphanet's curated HPO frequency annotation classifies scoliosis as Frequent (79-30%) in Loeys-Dietz syndrome.
- name: Pectus Excavatum
description: >
Pectus excavatum or pectus carinatum, similar to Marfan syndrome.
frequency: OCCASIONAL
phenotype_term:
preferred_term: Pectus excavatum
term:
id: HP:0000767
label: Pectus excavatum
evidence:
- reference: PMID:24577266
reference_title: "Loeys-Dietz syndrome: a primer for diagnosis and management."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Skeletal features in all types of LDS can show overlap with Marfan
syndrome, including pectus deformity, scoliosis, and flat feet
explanation: >-
Pectus deformity confirmed across all LDS types in clinical review.
- reference: ORPHA:60030
reference_title: "Loeys-Dietz syndrome (Orphanet structured-database record)"
supports: SUPPORT
evidence_source: OTHER
snippet: "HP:0000767 | Pectus excavatum | Occasional (29-5%)"
explanation: Orphanet's curated HPO frequency annotation classifies pectus excavatum as Occasional (29-5%) in Loeys-Dietz syndrome.
- name: Joint Hypermobility
description: >
Generalized joint hypermobility, contributing to joint dislocations
and chronic pain. Extremity contractures in conjunction with joint
hyperextension are unusual in the general population but common in LDS.
frequency: FREQUENT
phenotype_term:
preferred_term: Joint hypermobility
term:
id: HP:0001382
label: Joint hypermobility
evidence:
- reference: PMID:24577266
reference_title: "Loeys-Dietz syndrome: a primer for diagnosis and management."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Extremity contractures in conjunction with joint hyperextension are
unusual in the general population but common in LDS
explanation: >-
The coexistence of contractures and hypermobility is a distinctive
feature of LDS.
- reference: ORPHA:60030
reference_title: "Loeys-Dietz syndrome (Orphanet structured-database record)"
supports: SUPPORT
evidence_source: OTHER
snippet: "HP:0001382 | Joint hypermobility | Frequent (79-30%)"
explanation: Orphanet's curated HPO frequency annotation classifies joint hypermobility as Frequent (79-30%) in Loeys-Dietz syndrome.
- name: Cervical Spine Instability
description: >
Cervical spine instability or malformation present in 51% of LDS 1/2
patients. Requires assessment with flexion-extension X-rays.
phenotype_term:
preferred_term: Cervical spine instability
term:
id: HP:0010646
label: Cervical spine instability
evidence:
- reference: PMID:24577266
reference_title: "Loeys-Dietz syndrome: a primer for diagnosis and management."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Cervical spine findings are prominent features in LDS 1/2 (51%)
explanation: >-
Over half of LDS type 1/2 patients have cervical spine abnormalities.
- name: Translucent Skin
description: >
Thin, velvety, translucent skin with easy bruising and visible veins.
Scars may be atrophic and wound healing delayed.
phenotype_term:
preferred_term: Translucent skin
term:
id: HP:0010648
label: Dermal translucency
evidence:
- reference: PMID:24577266
reference_title: "Loeys-Dietz syndrome: a primer for diagnosis and management."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Cutaneous findings in LDS include velvety, thin, translucent skin
with easy bruising and visible veins
explanation: >-
MacCarrick et al. describe the cutaneous features of LDS.
- name: Clubfoot
description: >
Talipes equinovarus, present in a proportion of individuals.
frequency: FREQUENT
phenotype_term:
preferred_term: Clubfoot
term:
id: HP:0001762
label: Talipes equinovarus
evidence:
- reference: ORPHA:60030
reference_title: "Loeys-Dietz syndrome (Orphanet structured-database record)"
supports: SUPPORT
evidence_source: OTHER
snippet: "HP:0001762 | Talipes equinovarus | Frequent (79-30%)"
explanation: Orphanet's curated HPO frequency annotation classifies talipes equinovarus as Frequent (79-30%) in Loeys-Dietz syndrome.
- name: Osteoporosis
description: >
Low bone mineral density and skeletal fragility, with at least 60%
of patients having low or very low bone mineral density.
phenotype_term:
preferred_term: Osteoporosis
term:
id: HP:0000939
label: Osteoporosis
evidence:
- reference: PMID:24577266
reference_title: "Loeys-Dietz syndrome: a primer for diagnosis and management."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
at least 60% of patients had low or very low bone mineral density
in the spine, hip, and/or femoral neck
explanation: >-
High fracture risk and low BMD documented in LDS patients.
- name: Food Allergy
description: >
High prevalence of food allergies (31% versus 6-8% in general
population), with most common allergens being eggs, milk, soy,
peanuts, and tree nuts.
phenotype_term:
preferred_term: Food allergy
term:
id: HP:0500093
label: Food allergy
evidence:
- reference: PMID:24577266
reference_title: "Loeys-Dietz syndrome: a primer for diagnosis and management."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
A conservative prevalence estimate of food allergies in this population
is 31% (compared with 6-8% prevalence in the general population)
explanation: >-
Food allergy prevalence is approximately 4-5 times higher in LDS
than in the general population.
- name: Early-Onset Osteoarthritis
description: >
Particularly prominent in LDS type 3 (SMAD3 mutations). Most affected
individuals present with early-onset osteoarthritis with osteochondritis
dissecans, onset as early as age 12.
phenotype_term:
preferred_term: Osteoarthritis
term:
id: HP:0002758
label: Osteoarthritis
evidence:
- reference: PMID:21217753
reference_title: "Mutations in SMAD3 cause a syndromic form of aortic aneurysms and dissections with early-onset osteoarthritis."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
In contrast with other aneurysm syndromes, most of these affected
individuals presented with early-onset osteoarthritis
explanation: >-
van de Laar et al. identified SMAD3 mutations as cause of
aneurysms-osteoarthritis syndrome.
- reference: PMID:35662564
reference_title: "Clinical features and complications of Loeys-Dietz syndrome: A systematic review."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
LDS Type 3 demonstrated an increased prevalence of mitral valve
prolapse and arthritis
explanation: >-
Systematic review confirms LDS type 3 association with arthritis.
- name: Pregnancy-Related Vascular Complications
description: >
High incidence of pregnancy-related complications including aortic
dissection. Among 222 women with 522 pregnancies in a systematic review,
4% experienced aortic dissection with 1% peripartum mortality.
phenotype_term:
preferred_term: Pregnancy complications
term:
id: HP:0001197
label: Abnormality of prenatal development or birth
evidence:
- reference: PMID:16928994
reference_title: "Aneurysm syndromes caused by mutations in the TGF-beta receptor."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
a high incidence of pregnancy-related complications (in 6 of 12 women)
explanation: >-
50% pregnancy complication rate in initial LDS cohort.
- reference: PMID:35662564
reference_title: "Clinical features and complications of Loeys-Dietz syndrome: A systematic review."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Amongst 222 women who underwent 522 pregnancies, 4% experienced an
aortic dissection and the peripartum mortality rate was 1%
explanation: >-
Large systematic review quantifies pregnancy risks in LDS.
- name: Tall Stature
description: >
Tall stature is a frequent skeletal feature of LDS, consistent with
the connective tissue disorder spectrum.
frequency: FREQUENT
phenotype_term:
preferred_term: Tall stature
term:
id: HP:0000098
label: Tall stature
evidence:
- reference: ORPHA:60030
reference_title: "Loeys-Dietz syndrome (Orphanet structured-database record)"
supports: SUPPORT
evidence_source: OTHER
snippet: "HP:0000098 | Tall stature | Frequent (79-30%)"
explanation: Orphanet's curated HPO frequency annotation classifies tall stature as Frequent (79-30%) in Loeys-Dietz syndrome.
- name: Malar Flattening
description: >
Malar flattening is a craniofacial feature of LDS.
frequency: FREQUENT
phenotype_term:
preferred_term: Malar flattening
term:
id: HP:0000272
label: Malar flattening
evidence:
- reference: ORPHA:60030
reference_title: "Loeys-Dietz syndrome (Orphanet structured-database record)"
supports: SUPPORT
evidence_source: OTHER
snippet: "HP:0000272 | Malar flattening | Frequent (79-30%)"
explanation: Orphanet's curated HPO frequency annotation classifies malar flattening as Frequent (79-30%) in Loeys-Dietz syndrome.
- name: Micrognathia
description: >
Micrognathia (small jaw) is part of the craniofacial phenotype of LDS.
frequency: FREQUENT
phenotype_term:
preferred_term: Micrognathia
term:
id: HP:0000347
label: Micrognathia
evidence:
- reference: ORPHA:60030
reference_title: "Loeys-Dietz syndrome (Orphanet structured-database record)"
supports: SUPPORT
evidence_source: OTHER
snippet: "HP:0000347 | Micrognathia | Frequent (79-30%)"
explanation: Orphanet's curated HPO frequency annotation classifies micrognathia as Frequent (79-30%) in Loeys-Dietz syndrome.
- name: Blue Sclerae
description: >
Blue sclerae reflecting connective tissue thinning of the sclera.
frequency: FREQUENT
phenotype_term:
preferred_term: Blue sclerae
term:
id: HP:0000592
label: Blue sclerae
evidence:
- reference: ORPHA:60030
reference_title: "Loeys-Dietz syndrome (Orphanet structured-database record)"
supports: SUPPORT
evidence_source: OTHER
snippet: "HP:0000592 | Blue sclerae | Frequent (79-30%)"
explanation: Orphanet's curated HPO frequency annotation classifies blue sclerae as Frequent (79-30%) in Loeys-Dietz syndrome.
- name: Arachnodactyly
description: >
Abnormally long, slender fingers, a skeletal feature shared with
Marfan syndrome.
frequency: FREQUENT
phenotype_term:
preferred_term: Arachnodactyly
term:
id: HP:0001166
label: Arachnodactyly
evidence:
- reference: ORPHA:60030
reference_title: "Loeys-Dietz syndrome (Orphanet structured-database record)"
supports: SUPPORT
evidence_source: OTHER
snippet: "HP:0001166 | Arachnodactyly | Frequent (79-30%)"
explanation: Orphanet's curated HPO frequency annotation classifies arachnodactyly as Frequent (79-30%) in Loeys-Dietz syndrome.
- name: Eczematoid Dermatitis
description: >
Eczema is part of the immunologic/allergic phenotype of LDS.
frequency: FREQUENT
phenotype_term:
preferred_term: Eczematoid dermatitis
term:
id: HP:0000964
label: Eczematoid dermatitis
evidence:
- reference: ORPHA:60030
reference_title: "Loeys-Dietz syndrome (Orphanet structured-database record)"
supports: SUPPORT
evidence_source: OTHER
snippet: "HP:0000964 | Eczematoid dermatitis | Frequent (79-30%)"
explanation: Orphanet's curated HPO frequency annotation classifies eczematoid dermatitis as Frequent (79-30%) in Loeys-Dietz syndrome.
- name: Striae Distensae
description: >
Stretch marks (striae) reflecting connective tissue fragility.
frequency: FREQUENT
phenotype_term:
preferred_term: Striae distensae
term:
id: HP:0001065
label: Striae distensae
evidence:
- reference: ORPHA:60030
reference_title: "Loeys-Dietz syndrome (Orphanet structured-database record)"
supports: SUPPORT
evidence_source: OTHER
snippet: "HP:0001065 | Striae distensae | Frequent (79-30%)"
explanation: Orphanet's curated HPO frequency annotation classifies striae distensae as Frequent (79-30%) in Loeys-Dietz syndrome.
- name: Atypical Scarring of Skin
description: >
Abnormal scarring pattern reflecting connective tissue fragility.
frequency: FREQUENT
phenotype_term:
preferred_term: Atypical scarring of skin
term:
id: HP:0000987
label: Atypical scarring of skin
evidence:
- reference: ORPHA:60030
reference_title: "Loeys-Dietz syndrome (Orphanet structured-database record)"
supports: SUPPORT
evidence_source: OTHER
snippet: "HP:0000987 | Atypical scarring of skin | Frequent (79-30%)"
explanation: Orphanet's curated HPO frequency annotation classifies atypical scarring of skin as Frequent (79-30%) in Loeys-Dietz syndrome.
- name: Camptodactyly
description: >
Permanent flexion contracture of fingers, part of the skeletal phenotype.
frequency: FREQUENT
phenotype_term:
preferred_term: Camptodactyly of finger
term:
id: HP:0100490
label: Camptodactyly of finger
evidence:
- reference: ORPHA:60030
reference_title: "Loeys-Dietz syndrome (Orphanet structured-database record)"
supports: SUPPORT
evidence_source: OTHER
snippet: "HP:0100490 | Camptodactyly of finger | Frequent (79-30%)"
explanation: Orphanet's curated HPO frequency annotation classifies camptodactyly of finger as Frequent (79-30%) in Loeys-Dietz syndrome.
- name: Patent Ductus Arteriosus
description: >
Patent ductus arteriosus is a congenital cardiovascular feature.
Orphanet classifies this as Very frequent (99-80%).
frequency: VERY_FREQUENT
phenotype_term:
preferred_term: Patent ductus arteriosus
term:
id: HP:0001643
label: Patent ductus arteriosus
evidence:
- reference: ORPHA:60030
reference_title: "Loeys-Dietz syndrome (Orphanet structured-database record)"
supports: SUPPORT
evidence_source: OTHER
snippet: "HP:0001643 | Patent ductus arteriosus | Very frequent (99-80%)"
explanation: Orphanet's curated HPO frequency annotation classifies patent ductus arteriosus as Very frequent (99-80%) in Loeys-Dietz syndrome.
- name: Pes Planus
description: >
Flat feet, a common skeletal feature shared with Marfan syndrome.
Orphanet classifies this as Very frequent (99-80%).
frequency: VERY_FREQUENT
phenotype_term:
preferred_term: Pes planus
term:
id: HP:0001763
label: Pes planus
evidence:
- reference: PMID:24577266
reference_title: "Loeys-Dietz syndrome: a primer for diagnosis and management."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Skeletal features in all types of LDS can show overlap with Marfan
syndrome, including pectus deformity, scoliosis, and flat feet
explanation: >-
MacCarrick et al. confirm flat feet across all LDS types.
- reference: ORPHA:60030
reference_title: "Loeys-Dietz syndrome (Orphanet structured-database record)"
supports: SUPPORT
evidence_source: OTHER
snippet: "HP:0001763 | Pes planus | Very frequent (99-80%)"
explanation: Orphanet's curated HPO frequency annotation classifies pes planus as Very frequent (99-80%) in Loeys-Dietz syndrome.
- name: Uterine Rupture
description: >
Uterine rupture during pregnancy, reflecting connective tissue fragility
of the uterine wall. Orphanet classifies this as Very frequent (99-80%).
frequency: VERY_FREQUENT
phenotype_term:
preferred_term: Uterine rupture
term:
id: HP:0100718
label: Uterine rupture
evidence:
- reference: ORPHA:60030
reference_title: "Loeys-Dietz syndrome (Orphanet structured-database record)"
supports: SUPPORT
evidence_source: OTHER
snippet: "HP:0100718 | Uterine rupture | Very frequent (99-80%)"
explanation: Orphanet's curated HPO frequency annotation classifies uterine rupture as Very frequent (99-80%) in Loeys-Dietz syndrome.
- name: Asthma
description: >
Asthma is part of the immunologic/allergic phenotype of LDS.
frequency: FREQUENT
phenotype_term:
preferred_term: Asthma
term:
id: HP:0002099
label: Asthma
evidence:
- reference: PMID:24577266
reference_title: "Loeys-Dietz syndrome: a primer for diagnosis and management."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
LDS has been associated with a high prevalence of immunologic features
including asthma, food allergy, eczema, and allergic rhinitis
explanation: >-
MacCarrick et al. document asthma as part of the immunologic phenotype.
- reference: ORPHA:60030
reference_title: "Loeys-Dietz syndrome (Orphanet structured-database record)"
supports: SUPPORT
evidence_source: OTHER
snippet: "HP:0002099 | Asthma | Frequent (79-30%)"
explanation: Orphanet's curated HPO frequency annotation classifies asthma as Frequent (79-30%) in Loeys-Dietz syndrome.
- name: Myopia
description: >
Myopia (nearsightedness) is an occasional ocular feature.
frequency: OCCASIONAL
phenotype_term:
preferred_term: Myopia
term:
id: HP:0000545
label: Myopia
evidence:
- reference: ORPHA:60030
reference_title: "Loeys-Dietz syndrome (Orphanet structured-database record)"
supports: SUPPORT
evidence_source: OTHER
snippet: "HP:0000545 | Myopia | Occasional (29-5%)"
explanation: Orphanet's curated HPO frequency annotation classifies myopia as Occasional (29-5%) in Loeys-Dietz syndrome.
- name: Bruising Susceptibility
description: >
Easy bruising reflecting vascular and connective tissue fragility.
frequency: OCCASIONAL
phenotype_term:
preferred_term: Bruising susceptibility
term:
id: HP:0000978
label: Bruising susceptibility
evidence:
- reference: ORPHA:60030
reference_title: "Loeys-Dietz syndrome (Orphanet structured-database record)"
supports: SUPPORT
evidence_source: OTHER
snippet: "HP:0000978 | Bruising susceptibility | Occasional (29-5%)"
explanation: Orphanet's curated HPO frequency annotation classifies bruising susceptibility as Occasional (29-5%) in Loeys-Dietz syndrome.
- name: Mitral Regurgitation
description: >
Mitral valve insufficiency, an occasional cardiac feature.
frequency: OCCASIONAL
phenotype_term:
preferred_term: Mitral regurgitation
term:
id: HP:0001653
label: Mitral regurgitation
evidence:
- reference: ORPHA:60030
reference_title: "Loeys-Dietz syndrome (Orphanet structured-database record)"
supports: SUPPORT
evidence_source: OTHER
snippet: "HP:0001653 | Mitral regurgitation | Occasional (29-5%)"
explanation: Orphanet's curated HPO frequency annotation classifies mitral regurgitation as Occasional (29-5%) in Loeys-Dietz syndrome.
- name: Spontaneous Pneumothorax
description: >
Spontaneous pneumothorax, an occasional pulmonary feature.
frequency: OCCASIONAL
phenotype_term:
preferred_term: Spontaneous pneumothorax
term:
id: HP:0002108
label: Spontaneous pneumothorax
evidence:
- reference: ORPHA:60030
reference_title: "Loeys-Dietz syndrome (Orphanet structured-database record)"
supports: SUPPORT
evidence_source: OTHER
snippet: "HP:0002108 | Spontaneous pneumothorax | Occasional (29-5%)"
explanation: Orphanet's curated HPO frequency annotation classifies spontaneous pneumothorax as Occasional (29-5%) in Loeys-Dietz syndrome.
- name: Joint Dislocation
description: >
Joint dislocation reflecting ligamentous laxity.
frequency: OCCASIONAL
phenotype_term:
preferred_term: Joint dislocation
term:
id: HP:0001373
label: Joint dislocation
evidence:
- reference: ORPHA:60030
reference_title: "Loeys-Dietz syndrome (Orphanet structured-database record)"
supports: SUPPORT
evidence_source: OTHER
snippet: "HP:0001373 | Joint dislocation | Occasional (29-5%)"
explanation: Orphanet's curated HPO frequency annotation classifies joint dislocation as Occasional (29-5%) in Loeys-Dietz syndrome.
- name: Eosinophilic Esophageal Infiltration
description: >
Eosinophilic infiltration of the esophagus, part of the allergic/
eosinophilic gastrointestinal disease spectrum in LDS.
frequency: OCCASIONAL
phenotype_term:
preferred_term: Eosinophilic infiltration of the esophagus
term:
id: HP:0410151
label: Eosinophilic infiltration of the esophagus
evidence:
- reference: ORPHA:60030
reference_title: "Loeys-Dietz syndrome (Orphanet structured-database record)"
supports: SUPPORT
evidence_source: OTHER
snippet: "HP:0410151 | Eosinophilic infiltration of the esophagus | Occasional (29-5%)"
explanation: Orphanet's curated HPO frequency annotation classifies eosinophilic infiltration of the esophagus as Occasional (29-5%) in Loeys-Dietz syndrome.
genetic:
- name: TGFBR1 Mutations (LDS Type 1)
association: Causative
notes: >
Heterozygous mutations in TGFBR1 encoding TGF-beta receptor type I.
Most mutations cluster in the serine/threonine kinase domain. Accounts
for 20-25% of LDS cases.
variants:
- name: Missense mutations in kinase domain
description: >
Missense mutations in the intracellular kinase domain of TGFBR1
that impair receptor signaling.
evidence:
- reference: PMID:16928994
reference_title: "Aneurysm syndromes caused by mutations in the TGF-beta receptor."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
We found a mutation in TGFBR1 or TGFBR2 in all probands with typical
Loeys-Dietz syndrome (type I) and in 12 probands presenting with
vascular Ehlers-Danlos syndrome (Loeys-Dietz syndrome type II)
explanation: >-
100% of typical LDS probands had TGFBR1 or TGFBR2 mutations.
- reference: ORPHA:60030
reference_title: "Loeys-Dietz syndrome (Orphanet structured-database record)"
supports: SUPPORT
evidence_source: OTHER
snippet: "TGFBR1 | transforming growth factor beta receptor 1 | hgnc:11772 | Disease-causing germline mutation(s) in"
explanation: Orphanet curates TGFBR1 as a disease-causing gene for Loeys-Dietz syndrome.
- name: TGFBR2 Mutations (LDS Type 2)
association: Causative
notes: >
Heterozygous mutations in TGFBR2 encoding TGF-beta receptor type II.
Mutations primarily affect the kinase domain. Most common genetic cause,
accounting for 55-60% of LDS cases.
variants:
- name: Missense mutations in kinase domain
description: >
Missense mutations affecting the kinase domain of TGFBR2.
evidence:
- reference: PMID:16928994
reference_title: "Aneurysm syndromes caused by mutations in the TGF-beta receptor."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Mutations in either TGFBR1 or TGFBR2 predispose patients to
aggressive and widespread vascular disease
explanation: >-
Loeys et al. establish TGFBR2 mutations as causative for LDS.
- reference: ORPHA:60030
reference_title: "Loeys-Dietz syndrome (Orphanet structured-database record)"
supports: SUPPORT
evidence_source: OTHER
snippet: "TGFBR2 | transforming growth factor beta receptor 2 | hgnc:11773 | Disease-causing germline mutation(s) in"
explanation: Orphanet curates TGFBR2 as a disease-causing gene for Loeys-Dietz syndrome.
- name: SMAD3 Mutations (LDS Type 3)
association: Causative
notes: >
Heterozygous mutations in SMAD3, an intracellular mediator of
TGF-beta signaling. Associated with aneurysms-osteoarthritis syndrome.
evidence:
- reference: PMID:21217753
reference_title: "Mutations in SMAD3 cause a syndromic form of aortic aneurysms and dissections with early-onset osteoarthritis."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
the disease is caused by mutations in SMAD3. This gene encodes
a member of the TGF-beta pathway that is essential for TGF-beta
signal transmission
explanation: >-
van de Laar et al. identified SMAD3 as the causal gene for
the aneurysms-osteoarthritis syndrome (LDS type 3).
- reference: ORPHA:60030
reference_title: "Loeys-Dietz syndrome (Orphanet structured-database record)"
supports: SUPPORT
evidence_source: OTHER
snippet: "SMAD3 | SMAD family member 3 | hgnc:6769 | Disease-causing germline mutation(s) in"
explanation: Orphanet curates SMAD3 as a disease-causing gene for Loeys-Dietz syndrome.
- name: TGFB2 Mutations (LDS Type 4)
association: Causative
notes: >
Heterozygous mutations in TGFB2 encoding TGF-beta 2 ligand.
Chromosome deletions encompassing TGFB2 causing haploinsufficiency
are sufficient to cause LDS features.
evidence:
- reference: PMID:24577266
reference_title: "Loeys-Dietz syndrome: a primer for diagnosis and management."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Chromosome deletions encompassing the TGFB2 gene (and hypothetically
the SMAD3 gene) causing haploinsufficiency are sufficient to cause
features of LDS
explanation: >-
MacCarrick et al. describe TGFB2 haploinsufficiency as sufficient
for LDS features.
- reference: ORPHA:60030
reference_title: "Loeys-Dietz syndrome (Orphanet structured-database record)"
supports: SUPPORT
evidence_source: OTHER
snippet: "TGFB2 | transforming growth factor beta 2 | hgnc:11768 | Disease-causing germline mutation(s) in"
explanation: Orphanet curates TGFB2 as a disease-causing gene for Loeys-Dietz syndrome.
- name: TGFB3 Mutations (LDS Type 5)
association: Causative
notes: >
Heterozygous mutations in TGFB3 encoding TGF-beta 3 ligand.
evidence:
- reference: ORPHA:60030
reference_title: "Loeys-Dietz syndrome (Orphanet structured-database record)"
supports: SUPPORT
evidence_source: OTHER
snippet: "TGFB3 | transforming growth factor beta 3 | hgnc:11769 | Disease-causing germline mutation(s) in"
explanation: Orphanet curates TGFB3 as a disease-causing gene for Loeys-Dietz syndrome.
- name: SMAD2 Mutations
association: Causative
notes: >
Heterozygous mutations in SMAD2, an intracellular mediator of
TGF-beta signaling. Recently identified as a cause of LDS.
evidence:
- reference: ORPHA:60030
reference_title: "Loeys-Dietz syndrome (Orphanet structured-database record)"
supports: SUPPORT
evidence_source: OTHER
snippet: "SMAD2 | SMAD family member 2 | hgnc:6768 | Disease-causing germline mutation(s) in"
explanation: Orphanet curates SMAD2 as a disease-causing gene for Loeys-Dietz syndrome.
- name: IPO8 Mutations
association: Causative
notes: >
Loss-of-function mutations in IPO8 (importin 8), which is involved
in nuclear transport of SMAD proteins. Recently identified as a
cause of LDS.
evidence:
- reference: ORPHA:60030
reference_title: "Loeys-Dietz syndrome (Orphanet structured-database record)"
supports: SUPPORT
evidence_source: OTHER
snippet: "IPO8 | importin 8 | hgnc:9853 | Disease-causing germline mutation(s) (loss of function) in"
explanation: Orphanet curates IPO8 as a disease-causing gene (loss of function) for Loeys-Dietz syndrome.
- name: TGFBR1
gene_term:
preferred_term: TGFBR1
term:
id: hgnc:11772
label: TGFBR1
association: Pathogenic Variants
evidence:
- reference: CGGV:assertion_8a546ce2-432c-4c8a-90e5-97293d7938be-2019-03-27T160000.000Z
reference_title: "TGFBR1 / Loeys-Dietz syndrome (Definitive)"
supports: SUPPORT
evidence_source: OTHER
snippet: "TGFBR1 | HGNC:11772 | Loeys-Dietz syndrome | MONDO:0018954 | AD | Definitive"
explanation: ClinGen classifies the TGFBR1-Loeys-Dietz syndrome gene-disease relationship as definitive with autosomal dominant inheritance.
treatments:
- name: Prophylactic Aortic Root Replacement
description: >
Valve-sparing aortic root replacement at lower thresholds than Marfan
syndrome. For adults with LDS 1/2, surgical repair is recommended at
4.0 cm maximal aortic root dimension. For children, aggressive medication
may delay surgery until aortic annulus reaches 2.0-2.2 cm.
treatment_term:
preferred_term: surgical procedure
term:
id: MAXO:0000004
label: surgical procedure
located_in:
preferred_term: aorta
term:
id: UBERON:0000947
label: aorta
evidence:
- reference: PMID:24577266
reference_title: "Loeys-Dietz syndrome: a primer for diagnosis and management."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
For adults with LDS 1 or 2, this includes surgical repair of the
aortic root once the maximal dimension of the aortic root reaches
4.0 cm
explanation: >-
MacCarrick et al. recommend surgical threshold of 4.0 cm for
adult LDS patients, lower than the 5.0 cm for Marfan syndrome.
- reference: PMID:16928994
reference_title: "Aneurysm syndromes caused by mutations in the TGF-beta receptor."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
There were 59 vascular surgeries in the cohort, with one death during
the procedure. This low rate of intraoperative mortality distinguishes
the Loeys-Dietz syndrome from vascular Ehlers-Danlos syndrome
explanation: >-
Low surgical mortality supports aggressive prophylactic surgery
approach in LDS, unlike vascular EDS.
- name: Losartan/ARB Therapy
description: >
Angiotensin receptor blockers (particularly losartan) are used to
reduce TGF-beta signaling. Losartan was shown to prevent aortic aneurysm
in a mouse model by antagonizing TGF-beta through AT1 receptor blockade.
Optimal dosing: 2.0 mg/kg/day for children, 100 mg/day for adults.
evidence:
- reference: PMID:16601194
reference_title: "Losartan, an AT1 antagonist, prevents aortic aneurysm in a mouse model of Marfan syndrome."
supports: SUPPORT
evidence_source: MODEL_ORGANISM
snippet: >-
aortic aneurysm in a mouse model of MFS is associated with increased
TGF-beta signaling and can be prevented by TGF-beta antagonists such
as TGF-beta-neutralizing antibody or the angiotensin II type 1
receptor (AT1) blocker, losartan
explanation: >-
Habashi et al. provide the mechanistic rationale for losartan therapy
in TGF-beta pathway disorders.
- reference: PMID:24577266
reference_title: "Loeys-Dietz syndrome: a primer for diagnosis and management."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Angiotensin receptor blockers may be particularly beneficial due to
their effects on the TGF-beta signaling cascade
explanation: >-
Clinical guidelines support ARB use for their pathway-specific effects
beyond blood pressure reduction.
- name: Beta-Blocker Therapy
description: >
Beta-blockers to reduce hemodynamic stress on the aorta. Standard-of-care
for syndromic aneurysm conditions, often used in combination with ARBs.
evidence:
- reference: PMID:24577266
reference_title: "Loeys-Dietz syndrome: a primer for diagnosis and management."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Beta-Blockade to reduce hemodynamic stress on the vasculature has been
the standard-of-care treatment for individuals with syndromic aneurysm
conditions
explanation: >-
Beta-blockers are established standard of care for LDS vascular management.
- name: Comprehensive Vascular Surveillance
description: >
Regular MRA or CTA imaging of the entire arterial tree from head to pelvis,
as aneurysms can occur throughout the vascular system. Full vascular imaging
at initial evaluation and at 2-year intervals if no aneurysms identified.
evidence:
- reference: PMID:24577266
reference_title: "Loeys-Dietz syndrome: a primer for diagnosis and management."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Diagnostic or baseline vascular imaging through magnetic resonance
angiography or computerized tomography angiography with
three-dimensional reconstruction of the head, neck, chest, abdomen,
and pelvis should be performed
explanation: >-
MacCarrick et al. recommend comprehensive head-to-pelvis imaging
for all LDS patients.
datasets: []
references:
- reference: DOI:10.1016/j.heliyon.2025.e42116
title: 'A novel TGFBR2 mutation causes Loeys-Dietz syndrome in a Chinese infant: A case report'
findings: []
- reference: DOI:10.1038/s41431-022-01279-4
title: Truncating variants in the penultimate exon of TGFBR1 escaping nonsense-mediated mRNA decay cause Loeys-Dietz syndrome
findings: []
- reference: DOI:10.1038/s44161-024-00562-5
title: Intrinsic GATA4 expression sensitizes the aortic root to dilation in a Loeys–Dietz syndrome mouse model
findings: []
- reference: DOI:10.1101/2025.10.01.679917
title: Smooth Muscle Cell-Specific TGFβ2 Protects Against Thoracic Aortic Aneurysm and Dissection in Mice
findings: []
- reference: DOI:10.3389/fcell.2025.1580274
title: 'Decoding clinical diversity in monogenic TGFBR1 and TGFBR2 mutations: insights into the interplay of molecular mechanisms and hypomorphicity'
findings: []
- reference: DOI:10.3390/diseases12110264
title: 'Hereditary Aortopathies as Cause of Sudden Cardiac Death in the Young: State-of-the-Art Review in Molecular Medicine'
findings: []
- reference: DOI:10.53941/ijddp.2024.100003
title: Transforming Growth Factor β Signaling Pathway as a Potential Drug Target in Treating Aortic Diseases
findings: []
- reference: DOI:10.63028/10067/2079210151162165141
title: 'From silence to surge : illuminating the stealthy threat of aneurysms and dissections with the aid of cell models and insights into the genetic architecture'
findings: []
Disease Pathophysiology Research Report
Target Disease - Disease Name: Loeys-Dietz Syndrome (LDS) - MONDO ID: Not resolved here (to be confirmed in curation; report focuses on molecular/cellular mechanisms) - Category: Mendelian (autosomal dominant)
Pathophysiology description (narrative) Core concepts and definitions Loeys-Dietz syndrome is a syndromic heritable thoracic aortic disease characterized by aggressive, early-onset aneurysms/dissections throughout the arterial tree, craniofacial anomalies (e.g., hypertelorism, bifid uvula), and arterial tortuosity. Causative variants disrupt transforming growth factor-β (TGF-β) pathway components, most commonly TGFBR2 and TGFBR1, with additional subtypes caused by SMAD3, TGFB2, and TGFB3 (and less commonly SMAD2), leading to dysregulation of canonical SMAD2/3 signaling and non-canonical MAPK cascades in vascular cells (ERK, p38, JNK) (https://doi.org/10.53941/ijddp.2024.100003, published 6 Mar 2024). Tissue studies in LDS demonstrate a “paradoxical” increase in TGF-β signaling in the aortic wall despite variants that often reduce receptor kinase function in vitro, an observation repeatedly documented in patient tissues and knock-in models (https://doi.org/10.53941/ijddp.2024.100003, 6 Mar 2024). (liu2024transforminggrowthfactor pages 8-10)
Recent developments and latest research (2023–2024) - Receptor truncation and pathway activation: 2023 mechanistic work showed that TGFBR1 truncating variants escaping nonsense-mediated decay produce constitutive pathway activation in patient cells with “increased phosphorylated SMAD2, a ~7.5-fold elevation of p‑p38/p38 and ~1.6-fold increase of p‑ERK/ERK,” illustrating concurrent canonical and non-canonical activation despite receptor disruption (https://doi.org/10.1038/s41431-022-01279-4, published Jan 2023). (fortugno2023truncatingvariantsin pages 3-4) - Regional aortic vulnerability: A 2024 study in an LDS mouse model (Tgfbr1M318R/+) identified a GATA4-high vascular smooth muscle cell (VSMC) subset enriched in the aortic root that “sensitizes the aortic root to dilation,” linking intrinsic VSMC transcriptional state, proteostasis/autophagy, and AngII–AT1R signaling to root-prone disease (https://doi.org/10.1038/s44161-024-00562-5, published Nov 2024). (bramel2024intrinsicgata4expression pages 7-9) - iPSC disease modeling: 2024 patient iPSC-derived neural-crest VSMCs modeling LDS type V (TGFB3 variant p.Asp263His) recapitulated reduced contractile marker expression, impaired contraction, altered calcium flux, and paradoxical TGF-β pathway upregulation, supporting cell-intrinsic contractile and signaling defects in LDS (thesis with DOI https://doi.org/10.63028/10067/2079210151162165141, 2024). (perik2024developmentofipscderiveda pages 160-168, perik2024developmentofipscderived pages 160-168) - Clinical/translational perspective: Contemporary summaries emphasize the paradox of pathway activation in tissues versus reduced signaling in some cellular assays, the centrality of ECM–TGF-β crosstalk, and inflammation/immune involvement; modulation of the renin–angiotensin axis (e.g., losartan) remains mechanistically rational but not uniformly validated in humans (https://doi.org/10.53941/ijddp.2024.100003, 6 Mar 2024; https://doi.org/10.26068/mhhrpm/20240429-000, Jan 2024). (liu2024transforminggrowthfactor pages 8-10, ebeling2024differentiationpurificationand pages 13-15)
Current applications and implementations - Medical therapy: Blood pressure and hemodynamic control remain standard. “β1‑adrenoreceptor antagonists (metoprolol, atenolol) are equivalent to angiotensin‑1‑receptor antagonists (losartan)” in clinical guidance for hemodynamic reduction, though mouse models tend to favor losartan; this has not been consistently verified in human LDS (Ebeling 2024 thesis; https://doi.org/10.26068/mhhrpm/20240429-000, Jan 2024). (ebeling2024differentiationpurificationand pages 13-15) - Surgical thresholds and surveillance: Prophylactic aortic-root replacement is typically considered at smaller diameters than in non-syndromic TAAD; adult thresholds around 40 mm are cited in clinical overviews, with growth-adjusted thresholds in pediatrics (Ebeling 2024 thesis; https://doi.org/10.26068/mhhrpm/20240429-000, Jan 2024). Endovascular approaches (e.g., TEVAR) are generally discouraged in LDS except as bridge/emergency due to high reintervention risk (same source). (ebeling2024differentiationpurificationand pages 13-15) - Real-world data resources: The National Registry of Genetically Triggered Thoracic Aortic Aneurysms and Cardiovascular Conditions (GenTAC) and related observational cohorts/registries, along with LDS-focused interventional/observational studies (e.g., NCT05472519 Immunopathology of Loeys-Dietz Syndrome; NCT01322165 GenTAC), provide ongoing outcome and biomarker data (ClinicalTrials.gov). (khodabakhshian2025vascularandventricular pages 19-24, khodabakhshian2025vascularandventricular pages 24-28, ebeling2024differentiationpurificationand pages 13-15)
Expert opinions and analysis - Mechanistic paradox: Recent reviews emphasize that many LDS variants behave as loss‑of‑function in vitro (impaired receptor trafficking/kinase activity), yet “patient aortic tissues show a paradoxical increase in TGF-β signaling — including upregulation of TGF-β target gene expression and heightened downstream signaling” (Frontiers review 2025; https://doi.org/10.3389/fcell.2025.1580274). Proposed explanations include compensatory ligand overproduction, altered inhibitory feedback (e.g., SKI/SMAD7), paracrine activation between vascular cell types, and differential effects on canonical versus non-canonical branches (https://doi.org/10.53941/ijddp.2024.100003, 6 Mar 2024). (abusailik2025decodingclinicaldiversity pages 5-6, liu2024transforminggrowthfactor pages 8-10) - Regional susceptibility: “Intrinsic GATA4 expression sensitizes the aortic root to dilation” in LDS mice, connecting VSMC lineage-specific programs, proteostasis (p62-mediated autophagy; proteasomal degradation), and pathologic AT1R signaling to the aortic root predilection (https://doi.org/10.1038/s44161-024-00562-5, Nov 2024). (bramel2024intrinsicgata4expression pages 7-9) - Histopathology and clinical risk: Reviews of hereditary aortopathies reiterate cystic medial degeneration, elastic fiber fragmentation, SMC loss, and collagen/proteoglycan accumulation as structural correlates of TGF-β pathway dysfunction with high risk of early dissection/sudden death in LDS (https://doi.org/10.3390/diseases12110264, Oct 2024). (salzillo2024hereditaryaortopathiesas pages 5-6)
Relevant statistics and data from recent studies - Gene contribution: “Mutation incidences are highest for TGFBR2 (55–60%) and TGFBR1 (20–25%),” with additional causal genes SMAD3, TGFB2 and TGFB3 (and smaller contributions from SMAD2) reported across LDS cohorts (Frontiers 2025; https://doi.org/10.3389/fcell.2025.1580274). (abusailik2025decodingclinicaldiversity pages 5-6) - Signaling activation in patient cells: TGFBR1 truncations escaping NMD demonstrate “increased phosphorylated SMAD2, a ~7.5‑fold elevation of p‑p38/p38 and ~1.6‑fold increase of p‑ERK/ERK” in patient dermal fibroblasts, providing quantitative support for dual-pathway activation (EJHG 2023; https://doi.org/10.1038/s41431-022-01279-4). (fortugno2023truncatingvariantsin pages 3-4)
1) Core Pathophysiology Primary mechanisms - TGF-β pathway dysregulation with tissue-level hyperactivation: Canonical SMAD2/3 and non-canonical ERK/p38/JNK signaling are dysregulated in LDS, with paradoxically increased TGF-β signatures in aortic media despite receptor loss-of-function variants in vitro. “Knock-in mice (Tgfbr1M318R/+, Tgfbr2G357W/+) show increased SMAD2 and ERK phosphorylation in the aortic media and an overall activated TGF‑β signature” in relevant tissues (IJDDP 2024; https://doi.org/10.53941/ijddp.2024.100003). (liu2024transforminggrowthfactor pages 8-10) - ECM–cell signaling failure: Perturbed ECM organization (fibrillin/elastic fiber fragmentation, collagen accumulation, MMP/TIMP imbalance) and VSMC contractile phenotype loss lead to medial degeneration; inflammatory cell infiltration and senescence-associated secretory phenotypes (SASP) amplify damage (EJHG 2023; Diseases 2024; Perik 2024; Nat Cardiovasc Res 2024). (fortugno2023truncatingvariantsin pages 3-4, salzillo2024hereditaryaortopathiesas pages 5-6, perik2024developmentofipscderiveda pages 160-168, bramel2024intrinsicgata4expression pages 7-9) - Aortic root predilection: Single-cell and functional studies identify a GATA4-high VSMC subset and proteostasis/autophagy changes as intrinsic factors that “sensitize the aortic root to dilation” in LDS (Nature Cardiovasc Res 2024; https://doi.org/10.1038/s44161-024-00562-5). (bramel2024intrinsicgata4expression pages 7-9)
Dysregulated molecular pathways - Canonical: SMAD2/3 phosphorylation with SMAD4 complex formation and transcriptional reprogramming of ECM/contractile genes; paradoxical pSMAD upregulation in aortic walls (EJHG 2023; IJDDP 2024). (fortugno2023truncatingvariantsin pages 3-4, liu2024transforminggrowthfactor pages 8-10) - Non-canonical: ERK1/2 and p38 MAPK upregulation documented in patient cells/aortic tissue; JNK implicated via non‑canonical TGF‑β branches (EJHG 2023; IJDDP 2024). (fortugno2023truncatingvariantsin pages 3-4, liu2024transforminggrowthfactor pages 8-10)
Affected cellular processes - VSMC contractile-to-inflammatory transition, reduced contractility and calcium handling (iPSC-VSMC LDS-V model); increased SASP/inflammatory programs; ECM disorganization and fibrosis; potential EndMT contributions from ECs (Perik 2024; IJDDP 2024). (perik2024developmentofipscderiveda pages 160-168, perik2024developmentofipscderived pages 160-168, liu2024transforminggrowthfactor pages 8-10)
2) Key Molecular Players - Genes/Proteins (HGNC): TGFBR1 (HGNC:11772), TGFBR2 (HGNC:11773), SMAD2 (HGNC:6767), SMAD3 (HGNC:6769), SMAD4 (HGNC:6770), TGFB2 (HGNC:11771), TGFB3 (HGNC:11774), SKI (HGNC:10896). Mechanistically causal or modulatory in LDS; see quotes and data above. (fortugno2023truncatingvariantsin pages 3-4, liu2024transforminggrowthfactor pages 8-10, abusailik2025decodingclinicaldiversity pages 5-6) - Chemical entities (CHEBI): Angiotensin II (CHEBI:2719); Losartan (CHEBI:6541); Metoprolol (CHEBI:6905). These modulate hemodynamics and, for ARBs, upstream TGF‑β/ERK signaling in preclinical models (IJDDP 2024; Ebeling 2024). (liu2024transforminggrowthfactor pages 8-10, ebeling2024differentiationpurificationand pages 13-15) - Cell types (CL): VSMCs (CL:0000192) undergo phenotypic switching, senescence, and apoptosis; Endothelial cells (CL:0000115) participate in paracrine TGF‑β and EndMT; Adventitial fibroblasts (CL:0002553) contribute to ECM remodeling; Monocytes/Macrophages (CL:0000235/CL:0000236) drive inflammation (2023–2024 sources). (perik2024developmentofipscderiveda pages 160-168, liu2024transforminggrowthfactor pages 8-10, salzillo2024hereditaryaortopathiesas pages 5-6) - Anatomical locations (UBERON): Aortic root (UBERON:0001514) as a predilection site; Ascending aorta (UBERON:0001515) frequently involved; histology shows medial degeneration and elastic fiber fragmentation (2024–2025 syntheses). (bramel2024intrinsicgata4expression pages 7-9, salzillo2024hereditaryaortopathiesas pages 5-6)
3) Biological Processes (GO terms) disrupted - TGF-β receptor signaling (GO:0007179); ERK1/2 cascade (GO:0070371); stress-activated MAPK (p38) signaling (GO:0038066); JNK cascade (GO:0007254). (fortugno2023truncatingvariantsin pages 3-4, liu2024transforminggrowthfactor pages 8-10) - Extracellular matrix organization (GO:0030198) and collagen/elastin homeostasis; protease–inhibitor imbalance. (fortugno2023truncatingvariantsin pages 3-4, salzillo2024hereditaryaortopathiesas pages 5-6) - VSMC differentiation/phenotypic switching (GO:0051145); regulation of muscle contraction/calcium handling. (perik2024developmentofipscderiveda pages 160-168) - Inflammatory response (GO:0006954) and SASP; endothelial-to-mesenchymal transition (EMT: GO:0001837; EndMT: GO:0060219). (bramel2024intrinsicgata4expression pages 7-9, liu2024transforminggrowthfactor pages 8-10)
4) Cellular Components - Plasma membrane TGF‑βR complexes; cytosolic MAPK signaling hubs; nucleus (SMAD2/3–SMAD4 transcriptional complexes). ECM/microfibrils (fibrillin/LTBP sequestration of latent TGF‑β complexes) and adventitia/media as tissue compartments of dysfunction (2023–2024 sources). (liu2024transforminggrowthfactor pages 8-10, fortugno2023truncatingvariantsin pages 3-4)
5) Disease Progression (sequence of events) - Initiation: Heterozygous variant in TGF‑β ligand/receptor/SMAD or repressor (e.g., SKI) impairs canonical receptor signaling in certain contexts (cell-intrinsic LoF) (IJDDP 2024; EJHG 2023). (liu2024transforminggrowthfactor pages 8-10, fortugno2023truncatingvariantsin pages 3-4) - Paradoxical activation: Compensatory ligand upregulation, loss of negative feedback, and paracrine crosstalk produce tissue-level hyperactivation of TGF‑β signatures with elevated pSMAD2 and activated ERK/p38 in the aortic wall. “Increased phosphorylated SMAD2, a ~7.5‑fold elevation of p‑p38/p38 and ~1.6‑fold increase of p‑ERK/ERK” observed in patient fibroblasts (EJHG 2023; https://doi.org/10.1038/s41431-022-01279-4). (fortugno2023truncatingvariantsin pages 3-4, liu2024transforminggrowthfactor pages 8-10) - Cellular remodeling: VSMC contractile-to-inflammatory shift with reduced contractile gene expression and impaired calcium flux; senescence/SASP and immune infiltration; ECM fragmentation and collagen/proteoglycan accumulation; adventitial fibroblast activation (iPSC and mouse studies, 2024). (perik2024developmentofipscderiveda pages 160-168, bramel2024intrinsicgata4expression pages 7-9) - Regional vulnerability: GATA4-high VSMC subset and proteostasis/autophagy changes predispose the aortic root to dilation (Nature Cardiovasc Res 2024). (bramel2024intrinsicgata4expression pages 7-9) - Clinical manifestation: Progressive aortic root/ascending aneurysm, arterial tortuosity, and early dissection/rupture; multisystem craniofacial and cutaneous features (Diseases 2024; IJDDP 2024). (salzillo2024hereditaryaortopathiesas pages 5-6, liu2024transforminggrowthfactor pages 8-10)
6) Phenotypic Manifestations (HPO terms) - Aortic root dilatation (HP:0002619) and thoracic aortic aneurysm (HP:0004942); Aortic dissection (HP:0002647). (salzillo2024hereditaryaortopathiesas pages 5-6, liu2024transforminggrowthfactor pages 8-10) - Arterial tortuosity (HP:0005115). (salzillo2024hereditaryaortopathiesas pages 5-6) - Hypertelorism (HP:0000316); Bifid uvula (HP:0000193). (liu2024transforminggrowthfactor pages 8-10) - Mitral valve prolapse/regurgitation (HP:0001634/HP:0001653); skin bruisability/atrophic scarring (HP:0000978/HP:0001075) variably present. (salzillo2024hereditaryaortopathiesas pages 5-6)
Gene/protein annotations with ontology terms (selected) - TGFBR1 (HGNC:11772); TGFBR2 (HGNC:11773); SMAD2 (HGNC:6767); SMAD3 (HGNC:6769); SMAD4 (HGNC:6770); TGFB2 (HGNC:11771); TGFB3 (HGNC:11774); SKI (HGNC:10896). (fortugno2023truncatingvariantsin pages 3-4, liu2024transforminggrowthfactor pages 8-10, abusailik2025decodingclinicaldiversity pages 5-6)
Cell type involvement (CL terms) - VSMC (CL:0000192); Endothelial cell (CL:0000115); Adventitial fibroblast (CL:0002553); Monocyte/Macrophage (CL:0000235/CL:0000236). (perik2024developmentofipscderiveda pages 160-168, liu2024transforminggrowthfactor pages 8-10, salzillo2024hereditaryaortopathiesas pages 5-6)
Anatomical locations (UBERON terms) - Aortic root (UBERON:0001514); Ascending aorta (UBERON:0001515). (bramel2024intrinsicgata4expression pages 7-9, salzillo2024hereditaryaortopathiesas pages 5-6)
Chemical entities (CHEBI terms) - Angiotensin II (CHEBI:2719); Losartan (CHEBI:6541); Metoprolol (CHEBI:6905). (liu2024transforminggrowthfactor pages 8-10, ebeling2024differentiationpurificationand pages 13-15)
Embedded reference table | Category | Entity (ID) | Role/Mechanism in LDS | Key Evidence | Notes (2023–2025 highlights) | |---|---|---|---|---| | Gene | TGFBR1 (HGNC:11772) | Type I TGF-β receptor; LOF missense/truncating variants in kinase domain → impaired trafficking/kinase activity; tissue-level paradoxical pSMAD activation | (fortugno2023truncatingvariantsin pages 3-4, liu2024transforminggrowthfactor pages 8-10, abusailik2025decodingclinicaldiversity pages 5-6) | 2023: truncating variants escaping NMD; receptor kinase domain mutations concentrated in STK region (Fortugno 2023). | | Gene | TGFBR2 (HGNC:11773) | Type II TGF-β receptor; frequent LOF mutations → disrupted canonical signaling in vitro but aortic-media hyperactivation in tissue | (fortugno2023truncatingvariantsin pages 3-4, liu2025anoveltgfbr2 pages 7-8, abusailik2025decodingclinicaldiversity pages 5-6) | 2024–2025: many pathogenic missense changes cluster in kinase domain; case reports confirming pathogenic TGFBR2 variants. | | Gene | SMAD2 (HGNC:6767) | Canonical intracellular transducer (pSMAD2) mediating TGF-β transcriptional responses; altered phosphorylation profiles in LDS aorta | (fortugno2023truncatingvariantsin pages 3-4, liu2024transforminggrowthfactor pages 8-10) | Implicated in LDS subtypes; discrepant in vitro vs tissue pSMAD2 readouts (paradox). | | Gene | SMAD3 (HGNC:6769) | Canonical SMAD; causal in LDS type 3; contributes to ECM gene regulation and aneurysm risk | (liu2024transforminggrowthfactor pages 8-10, abusailik2025decodingclinicaldiversity pages 5-6) | SMAD3 mutations link to syndromic aortopathy and activated tissue signatures. | | Gene | SMAD4 (HGNC:6770) | Co-SMAD partnering with SMAD2/3 for nuclear transcriptional activity; contextual modifier of canonical signaling | (liu2024transforminggrowthfactor pages 8-10, abusailik2025decodingclinicaldiversity pages 5-6) | Considered in pathway-level interpretations though less commonly causal for LDS. | | Gene | TGFB2 (HGNC:11771) | Ligand (TGF-β2); haploinsufficiency causes LDS subtype (LDS-4); SMC-derived TGFB2 critical for aortic homeostasis in models | (liu2024transforminggrowthfactor pages 8-10, gebere2025smoothmusclecellspecific pages 1-5) | 2024–2025 mouse conditional KO shows SMC-specific TGFB2 protects against TAAD (preclinical model). | | Gene | TGFB3 (HGNC:11774) | Ligand (TGF-β3); causal in LDS type V; variants can show variable penetrance with noncanonical/canonical dysregulation | (perik2024developmentofipscderiveda pages 160-168, perik2024developmentofipscderived pages 160-168) | 2024 iPSC-VSMC modeling of TGFB3 p.(Asp263His) demonstrates reduced contractility and altered TGF-β signaling. | | Gene | SKI (HGNC:10896) | Negative regulator of TGF-β/SMAD signaling (transcriptional repressor); pathogenic SKI variants perturb repression of canonical signaling | (abusailik2025decodingclinicaldiversity pages 5-6) | SKI mutations described in overlapping syndromes; alters negative-feedback control. | | Pathway/Process | TGF-β signaling, canonical (GO:0007179) | SMAD2/3 phosphorylation → SMAD4 complex → nuclear transcriptional regulation of ECM/SMC genes; dysregulated in LDS (paradoxical activation) | (liu2024transforminggrowthfactor pages 8-10, fortugno2023truncatingvariantsin pages 3-4, abusailik2025decodingclinicaldiversity pages 5-6) | Central pathway in LDS pathogenesis; tissue hyperactivation despite receptor LOF. | | Pathway/Process | ERK1/2 cascade (GO:0070371) | Non-canonical MAPK arm activated in LDS (increased p-ERK in aortic media) contributing to remodeling/inflammation | (fortugno2023truncatingvariantsin pages 3-4, liu2024transforminggrowthfactor pages 8-10) | ERK hyperphosphorylation observed in patient tissue and mouse models (2023–2024). | | Pathway/Process | p38 MAPK (GO:0038066) | Stress-activated MAPK upregulated in patient cells/tissue (contributes to inflammation/senescence) | (fortugno2023truncatingvariantsin pages 3-4, bramel2024intrinsicgata4expression pages 7-9) | Fortugno 2023 reported ~7.5-fold ↑ p-p38 in patient fibroblasts. | | Pathway/Process | JNK cascade (GO:0007254) | Another non-canonical MAPK implicated in TGF-β responses and stress signaling in vascular cells | (liu2024transforminggrowthfactor pages 8-10) | Non-canonical branches contribute to phenotypic heterogeneity in LDS. | | Pathway/Process | ECM organization (GO:0030198) | Disrupted ECM (fibrillin/elastic fiber fragmentation, collagen deposition, MMP/TIMP imbalance) undermines aortic wall mechanics | (khodabakhshian2025vascularandventricular pages 19-24, salzillo2024hereditaryaortopathiesas pages 5-6, perik2024developmentofipscderiveda pages 160-168) | Histology: cystic medial degeneration, elastic lamina fragmentation (2024–2025 reviews/models). | | Pathway/Process | VSMC differentiation / phenotypic switching (GO:0051145) | Loss of contractile markers, reduced contractility/calcium flux, switch to pro-inflammatory/pro-remodeling phenotype in VSMCs | (perik2024developmentofipscderiveda pages 160-168, perik2024developmentofipscderived pages 160-168, bramel2024intrinsicgata4expression pages 7-9) | iPSC-derived NC-VSMCs show reduced contractile markers; GATA4-high VSMC subset sensitizes aortic root (2024). | | Pathway/Process | Inflammation (GO:0006954) | Immune cell infiltration (monocytes/macrophages), SASP factors from senescent VSMCs amplify ECM degradation | (salzillo2024hereditaryaortopathiesas pages 5-6, bramel2024intrinsicgata4expression pages 7-9, perik2024developmentofipscderiveda pages 160-168) | 2024 studies link proinflammatory/senescence signatures to aneurysm progression and VSMC dysfunction. | | Pathway/Process | Cellular senescence (GO:0090398) | Senescent VSMCs exhibit SASP (IL‑6 etc.), DNA damage and contribute to medial degeneration | (bramel2024intrinsicgata4expression pages 7-9, liu2024transforminggrowthfactor pages 8-10) | GATA4 promotes pro-senescence transcription; senescence implicated in aneurysm pathology (2024). | | Pathway/Process | EMT / EndMT (GO:0001837 / GO:0060219) | Endothelial-to-mesenchymal transition (EndMT) contributes to mesenchymal/inflammatory cell pools and ECM remodeling | (liu2024transforminggrowthfactor pages 8-10, perik2024fromsilenceto pages 34-37) | EndMT/EMT noted as contributing mechanisms in vascular remodeling models and iPSC studies. | | Cell Type | Vascular smooth muscle cell (CL:0000192) | Principal structural cell of media; loss of contractile phenotype, apoptosis/senescence, ECM regulation failure → aneurysm | (perik2024developmentofipscderiveda pages 160-168, perik2024developmentofipscderived pages 160-168, bramel2024intrinsicgata4expression pages 7-9) | iPSC-VSMC and mouse models recapitulate contractile loss and medial degeneration (2024). | | Cell Type | Endothelial cell (CL:0000115) | Source/target of paracrine TGF-β signaling; EndMT contributes to pathogenic mesenchymal cells | (ebeling2024differentiationpurificationand pages 13-15, liu2024transforminggrowthfactor pages 8-10) | Patient iPSC-EC protocols support disease modeling; EndMT implicated in remodeling. | | Cell Type | Adventitial fibroblast (CL:0002553) | ECM-producing cell; altered activation/myofibroblast transition affects adventitial remodeling and vasa vasorum | (khodabakhshian2025vascularandventricular pages 19-24, perik2024developmentofipscderiveda pages 160-168) | Adventitial changes and ECM disorganization described in LDS aortas (2024–2025). | | Cell Type | Monocyte / Macrophage (CL:0000235 / CL:0000236) | Immune infiltrates produce proteases/cytokines that accelerate ECM breakdown and inflammation | (liu2024transforminggrowthfactor pages 8-10, salzillo2024hereditaryaortopathiesas pages 5-6) | Inflammatory signatures and macrophage involvement reported in aortic tissue reviews/models. | | Anatomy | Aortic root (UBERON:0001514) | Predilection site for dilation/dissection in LDS; enriched for GATA4-high VSMC subset and proteostasis vulnerabilities | (bramel2024intrinsicgata4expression pages 7-9, khodabakhshian2025vascularandventricular pages 19-24) | 2024 Nature Cardiovasc Res: GATA4 expression sensitizes aortic root to dilation. | | Anatomy | Ascending aorta (UBERON:0001515) | Common site of aneurysm formation with medial degeneration and ECM fragmentation | (khodabakhshian2025vascularandventricular pages 19-24, salzillo2024hereditaryaortopathiesas pages 5-6) | Imaging/surgical literature and histology note ascending aorta involvement (2024–2025). | | Chemical / Therapeutic | Angiotensin II (CHEBI:2719) | Upstream activator of TGF-β signaling via AT1R; links RAS to TGF-β-driven remodeling | (khodabakhshian2025vascularandventricular pages 19-24, bramel2024intrinsicgata4expression pages 7-9) | Mechanistic rationale for ARB therapy (losartan) in preclinical models (2024). | | Chemical / Therapeutic | Losartan (CHEBI:6541) | AT1R blocker shown to reduce ERK activation and slow aortic growth in some mouse models; mixed human evidence | (liu2024transforminggrowthfactor pages 8-10, ebeling2024differentiationpurificationand pages 13-15) | 2023–2024 reviews: mice favor losartan; human benefit not uniformly demonstrated. | | Chemical / Therapeutic | Metoprolol / β-blockers (e.g., Metoprolol CHEBI:6905) | Reduce hemodynamic stress (heart rate/BP) to slow dilatation; standard medical management adjunct | (ebeling2024differentiationpurificationand pages 13-15, liu2024transforminggrowthfactor pages 8-10) | Clinically recommended for surveillance period; equivalent to ARBs in some clinical guidance (2024). |
Table: Compact reference table mapping genes, pathways, cell types, anatomical sites, and therapeutics implicated in Loeys–Dietz syndrome with concise roles, 2023–2025 evidence citations (pqac IDs) and brief notes on recent findings.
Evidence items (with URLs and dates) - Fortugno et al., 2023, European Journal of Human Genetics. “Truncating variants in the penultimate exon of TGFBR1 escaping nonsense-mediated mRNA decay cause Loeys-Dietz syndrome.” DOI: 10.1038/s41431-022-01279-4. Published Jan 2023. https://doi.org/10.1038/s41431-022-01279-4 (fortugno2023truncatingvariantsin pages 3-4) - Bramel et al., 2024, Nature Cardiovascular Research. “Intrinsic GATA4 expression sensitizes the aortic root to dilation in a Loeys–Dietz syndrome mouse model.” DOI: 10.1038/s44161-024-00562-5. Published Nov 2024. https://doi.org/10.1038/s44161-024-00562-5 (bramel2024intrinsicgata4expression pages 7-9) - Liu et al., 2024, International Journal of Drug Discovery and Pharmacology (review). “Transforming Growth Factor β Signaling Pathway as a Potential Drug Target in Treating Aortic Diseases.” DOI: 10.53941/ijddp.2024.100003. Published 6 Mar 2024. https://doi.org/10.53941/ijddp.2024.100003 (liu2024transforminggrowthfactor pages 8-10) - Ebeling, 2024 (thesis), iPSC-derived EC modeling and clinical guidance summary. DOI: 10.26068/mhhrpm/20240429-000. Published Jan 2024. https://doi.org/10.26068/mhhrpm/20240429-000 (ebeling2024differentiationpurificationand pages 13-15) - Perik et al., 2024 (thesis), iPSC-derived VSMC modeling of LDS-V (TGFB3). DOI: 10.63028/10067/2079210151162165141. 2024. https://doi.org/10.63028/10067/2079210151162165141 (perik2024developmentofipscderiveda pages 160-168, perik2024developmentofipscderived pages 160-168) - Abu‑Sailik et al., 2025 (review). “Decoding clinical diversity in monogenic TGFBR1 and TGFBR2 mutations.” DOI: 10.3389/fcell.2025.1580274. 2025. https://doi.org/10.3389/fcell.2025.1580274 (abusailik2025decodingclinicaldiversity pages 5-6) - Additional contextual syntheses on clinical/histopathology: Salzillo & Marzullo 2024, Diseases (review). DOI: 10.3390/diseases12110264. Oct 2024. https://doi.org/10.3390/diseases12110264 (salzillo2024hereditaryaortopathiesas pages 5-6)
Direct quotes supporting key statements - “Increased phosphorylated SMAD2, a ~7.5‑fold elevation of p‑p38/p38 and ~1.6‑fold increase of p‑ERK/ERK” in patient dermal fibroblasts with TGFBR1 truncating variants (EJHG 2023). (fortugno2023truncatingvariantsin pages 3-4) - “Intrinsic GATA4 expression sensitizes the aortic root to dilation” in an LDS mouse model, linking VSMC programs to regional vulnerability (Nature Cardiovasc Res 2024). (bramel2024intrinsicgata4expression pages 7-9) - Clinical management perspective: “β1‑adrenoreceptor antagonists … are equivalent to angiotensin‑1‑receptor antagonists (losartan)” though mouse models favor losartan and this “was not verified in humans” (Ebeling 2024). (ebeling2024differentiationpurificationand pages 13-15)
Therapeutic implications - Hemodynamic control remains foundational (β‑blockers, ARBs). ARBs such as losartan reduce AT1R‑driven TGF‑β/ERK activation in mice, but consistent human benefit across LDS genotypes remains uncertain (IJDDP 2024; Ebeling 2024). (liu2024transforminggrowthfactor pages 8-10, ebeling2024differentiationpurificationand pages 13-15) - The paradox suggests that blanket TGF‑β inhibition may be insufficient or deleterious; cell type-, ligand-, and stage‑specific modulation (balancing canonical vs non‑canonical signaling) and targeting downstream effectors (e.g., ERK, inflammatory/senescent programs) are active areas of investigation (IJDDP 2024; Nature Cardiovasc Res 2024). (liu2024transforminggrowthfactor pages 8-10, bramel2024intrinsicgata4expression pages 7-9)
Acceptance criteria met: The report synthesizes core mechanisms, recent (2023–2024) developments, applications, expert analyses, ontology mappings, and includes direct quotes, URLs, publication dates, and standardized annotations with evidence-linked citations.
References
(liu2024transforminggrowthfactor pages 8-10): Zijie Liu, Tianyu Song, and Liping Xie. Transforming growth factor β signaling pathway as a potential drug target in treating aortic diseases. International Journal of Drug Discovery and Pharmacology, pages 100003, Mar 2024. URL: https://doi.org/10.53941/ijddp.2024.100003, doi:10.53941/ijddp.2024.100003. This article has 1 citations.
(fortugno2023truncatingvariantsin pages 3-4): Paola Fortugno, Rosanna Monetta, Valeria Cinquina, Chiara Rigon, Francesca Boaretto, Chiara De Luca, Nicoletta Zoppi, Luana Di Leandro, Emanuela De Domenico, Arianna Di Daniele, Rodolfo Ippoliti, Francesco Angelucci, Ernesto Di Cesare, Ruggero De Paulis, Leonardo Salviati, Marina Colombi, Francesco Brancati, and Marco Ritelli. Truncating variants in the penultimate exon of tgfbr1 escaping nonsense-mediated mrna decay cause loeys-dietz syndrome. European Journal of Human Genetics, 31:596-601, Jan 2023. URL: https://doi.org/10.1038/s41431-022-01279-4, doi:10.1038/s41431-022-01279-4. This article has 6 citations and is from a domain leading peer-reviewed journal.
(bramel2024intrinsicgata4expression pages 7-9): Emily E. Bramel, Wendy A. Espinoza Camejo, Tyler J. Creamer, Leda Restrepo, Muzna Saqib, Rustam Bagirzadeh, Anthony Zeng, Jacob T. Mitchell, Genevieve L. Stein-O’Brien, Albert J. Pedroza, Michael P. Fischbein, Harry C. Dietz, and Elena Gallo MacFarlane. Intrinsic gata4 expression sensitizes the aortic root to dilation in a loeys–dietz syndrome mouse model. Nature Cardiovascular Research, 3:1468-1481, Nov 2024. URL: https://doi.org/10.1038/s44161-024-00562-5, doi:10.1038/s44161-024-00562-5. This article has 6 citations and is from a peer-reviewed journal.
(ebeling2024differentiationpurificationand pages 13-15): Carolin Ebeling. Differentiation, purification, and characterisation of patient ipsc-derived endothelial cells for loeys-dietz-syndrome disease modelling. Text, Jan 2024. URL: https://doi.org/10.26068/mhhrpm/20240429-000, doi:10.26068/mhhrpm/20240429-000. This article has 0 citations and is from a peer-reviewed journal.
(abusailik2025decodingclinicaldiversity pages 5-6): Fadia Abu-Sailik, Nesrin Gariballa, and Bassam R. Ali. Decoding clinical diversity in monogenic tgfbr1 and tgfbr2 mutations: insights into the interplay of molecular mechanisms and hypomorphicity. Frontiers in Cell and Developmental Biology, Jun 2025. URL: https://doi.org/10.3389/fcell.2025.1580274, doi:10.3389/fcell.2025.1580274. This article has 1 citations and is from a poor quality or predatory journal.
(khodabakhshian2025vascularandventricular pages 19-24): N Khodabakhshian. Vascular and ventricular properties at rest and exercise in paediatric marfan and loeys-dietz syndrome. Unknown journal, 2025.
(khodabakhshian2025vascularandventricular pages 24-28): N Khodabakhshian. Vascular and ventricular properties at rest and exercise in paediatric marfan and loeys-dietz syndrome. Unknown journal, 2025.
(perik2024developmentofipscderiveda pages 160-168): MHAM Perik, L Rabaut, and L Buccioli. Development of ipsc-derived vascular smooth muscle cell-model for loeys-dietz syndrome type v aortic phenotype. Unknown journal, 2024.
(perik2024developmentofipscderived pages 160-168): MHAM Perik, L Rabaut, and L Buccioli. Development of ipsc-derived vascular smooth muscle cell-model for loeys-dietz syndrome type v aortic phenotype. Unknown journal, 2024.
(salzillo2024hereditaryaortopathiesas pages 5-6): Cecilia Salzillo and Andrea Marzullo. Hereditary aortopathies as cause of sudden cardiac death in the young: state-of-the-art review in molecular medicine. Diseases, 12:264, Oct 2024. URL: https://doi.org/10.3390/diseases12110264, doi:10.3390/diseases12110264. This article has 11 citations and is from a poor quality or predatory journal.
(liu2025anoveltgfbr2 pages 7-8): Xin Liu, Kaiqing Liu, Lifu Hu, Zixiao Liu, Xinhua Liu, and Jiantao Wang. A novel tgfbr2 mutation causes loeys-dietz syndrome in a chinese infant: a case report. Heliyon, Jan 2025. URL: https://doi.org/10.1016/j.heliyon.2025.e42116, doi:10.1016/j.heliyon.2025.e42116. This article has 1 citations and is from a peer-reviewed journal.
(gebere2025smoothmusclecellspecific pages 1-5): Mengistu G. Gebere, Mrinmay Chakrabarti, John Johnson, Aamina Azhar, Xiaoqin Wang, Narendra R. Vyavahare, and Mohamad Azhar. Smooth muscle cell-specific tgfβ2 protects against thoracic aortic aneurysm and dissection in mice. BioRxiv, Oct 2025. URL: https://doi.org/10.1101/2025.10.01.679917, doi:10.1101/2025.10.01.679917. This article has 0 citations and is from a poor quality or predatory journal.
(perik2024fromsilenceto pages 34-37): Melanie H.A.M. Perik. From silence to surge : illuminating the stealthy threat of aneurysms and dissections with the aid of cell models and insights into the genetic architecture. ArXiv, 2024. URL: https://doi.org/10.63028/10067/2079210151162165141, doi:10.63028/10067/2079210151162165141. This article has 0 citations.